Biognosys’ Head of Business Development & Sales, Ben Gonzales, recently sat down with NeoGenomics Laboratories’ Director of Scientific Affairs, Anna Juncker-Jensen, to discuss all things Biomarker Discovery. What are the biggest challenges researchers face today? And how can the collaboration between NeoGenomics and Biognosys help overcome them?

Watch the interview to hear their perspectives. To get to know more about this strategic partnership, click here.

Yes, today we are talking about immunopeptidomics! Our Principal Scientist, Marco Tognetti, is featured in our latest SpotLight series video to explain everything about this innovative application of our TrueDiscovery™ platform.

Are you looking for targets for personalized cancer immunotherapies or developing novel mRNA and peptide-based vaccines and cell-based therapies? We can help. Our Immunopeptidome Profiling solution offers the deepest identification of Class I and II peptides to step up your research journey!

Contact our experts at services@biognosys.com to learn how we can support you.

The case study elaborates on the results of our pan-cancer proteomics study. We analyzed 180 plasma samples from lung, breast, colorectal, pancreatic, and prostate cancer using our next-generation TrueDiscovery™ platform to discover actionable biomarkers.

Poster presented at ASBMB 2022

Presenter: Nigel Beaton
Sunday, August 14

Presenter: Yuehan Feng
 

In our poster, we introduce a semi-automated workflow requiring low sample input to robustly identify immunopeptides from cultured cells and tissue samples and apply it to a cohort of colorectal cancer samples for immunopeptide profiling and neoantigen identification.

This poster is the product of a collaboration with Indivumed Therapeutics.

Presenter: Marco Tognetti
Date: November 5

The poster highlighted our Immunopeptidome Profiling solution for cell and tissue immunopeptidomics. Our pipeline generates high-quality identifications from minimal starting material. It can be deployed to help shed light on immunopeptidomics heterogeneity through large-scale profiling of patients, as exemplified in the case of MSI-H colorectal cancer. Download the poster to discover more.

E-Poster presented at AACR 2020

Presenter: Jan Muntel, PhD
A collaboration with: Crown Bioscience Inc.

Trapped ion mobility spectrometry (TIMS) extends conventional LC-MS/MS proteomic workflows with an additional ion mobility dimension. Next to the benefits of signal separation, the implementation of TIMS in Bruker timsTOF instruments has demonstrated that collisional cross section (CCS) values of peptides are highly reproducible and can be used as orthogonal coordinates to retention time and ion m/z values for targeted data extraction in data-independent acquisition (DIA) workflows, or as additional metric for rescoring in spectrum-centric database searches.

New: Spectronaut^® 19

Unlock Your Data's True Story

New: Spectronaut^® 19

Unlock Your Data's True Story

Learn More